They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

Bernstein SocGen Group has revised its price target for Merck (NYSE:MRK) shares, bringing it down to $95 from the previous $110 while maintaining a Market Perform rating. Analyst Courtney Breen cited ...

Merck (MRK) is a leading global healthcare company recognized for its groundbreaking pharmaceutical products and vaccines.

to 4.6% in 2025 and 4.5% in 2026. A collapse in the Chinese housing market has undermined consumer confidence. Overall sales of Gardasil fell 17% to $1.55 billion in the final quarter of last year, ...

1 Gardasil—a vaccine that combats human papillomavirus (HPV)—made $8.6 billion in global sales last year, but this represented a 3% decline over 2023 numbers. "Like many other companies, we've seen ...

In this piece, we will look at the stocks Jim Cramer recently discussed.

It is a cancer that is preventable and highly treatable if people have access to the right kind of medical professionals and ...

Two doses of the HPV vaccine were administered within a six-month period ... vaccination campaign on World Cancer Day today, aiming to immunize over 1.6 million girls aged 10-15 years. Human ...

Kathmandu [Nepal], February 4 (ANI): Nepal has launched the national Human Papillomavirus (HPV) vaccination campaign on World Cancer Day today, aiming to immunize over 1.6 million girls ... of the ...

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year, to the point the US ...